Open AccessS3326 Continuation of Mesalamine with Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease: A Two Center Analysis of Treatment Trends and Cost
Author(s) -
Gurbir Sehmbey,
Janet Fawcett,
Yasmin Alishahi,
Rakesh Nanda
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000786836.20291.0b
Subject(s) - medicine , inflammatory bowel disease , ulcerative colitis , infliximab , gastroenterology , tumor necrosis factor alpha , adverse effect , pharmacy , disease , colitis , family medicine